

Guillaume Ploussard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5269350/publications.pdf>

Version: 2024-02-01

108
papers

3,470
citations

147726

31
h-index

161767

54
g-index

116
all docs

116
docs citations

116
times ranked

3970
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
2	The Contemporary Concept of Significant Versus Insignificant Prostate Cancer. <i>European Urology</i> , 2011, 60, 291-303.	0.9	267
3	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. <i>European Urology</i> , 2019, 75, 506-514.	0.9	188
4	Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: Efficacy, Limitations, and Complicationsâ€”A Systematic Review of the Literature. <i>European Urology</i> , 2014, 65, 7-16.	0.9	180
5	Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance. <i>European Urology</i> , 2011, 59, 422-429.	0.9	136
6	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
7	Urine biomarkers in prostate cancer. <i>Nature Reviews Urology</i> , 2010, 7, 101-109.	1.9	102
8	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imagingâ€”targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2020, 77, 733-741.	0.9	85
9	Pathological Findings and Prostate Specific Antigen Outcomes After Radical Prostatectomy in Men Eligible for Active Surveillanceâ€”Does the Risk of Misclassification Vary According to Biopsy Criteria?. <i>Journal of Urology</i> , 2010, 183, 539-545.	0.2	78
10	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	0.9	78
11	Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e1-71.e9.	0.8	62
12	The Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance. <i>European Urology</i> , 2009, 56, 891-898.	0.9	58
13	Precision Matters in MR Imagingâ€”targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. <i>Radiology</i> , 2018, 287, 534-542.	3.6	56
14	Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification. <i>Urology</i> , 2011, 78, 607-613.	0.5	55
15	External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. <i>European Urology</i> , 2020, 78, 138-142.	0.9	55
16	Differences in trends in the use of robotâ€”assisted and open radical cystectomy and changes over time in periâ€”operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	1.3	53
17	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 80, 549-563.	0.9	53
18	Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , 2020, 203, 338-343.	0.2	53

#	ARTICLE	IF	CITATIONS
19	Oncologic Outcome after Extraperitoneal Laparoscopic Radical Prostatectomy: Midterm Follow-up of 1115 Procedures. <i>European Urology</i> , 2010, 57, 267-273.	0.9	52
20	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , 2019, 5, 171-178.	1.6	50
21	Low pretreatment total testosterone ($\leq 3\text{ ng/mL}$) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. <i>BJU International</i> , 2011, 107, 1400-1403.	1.3	49
22	External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2021, 79, 180-185.	0.9	47
23	Robotic surgery in urology. <i>Current Opinion in Urology</i> , 2018, 28, 153-158.	0.9	46
24	Predictive Factors of Oncologic Outcomes in Patients Who do not Achieve Undetectable Prostate Specific Antigen after Radical Prostatectomy. <i>Journal of Urology</i> , 2013, 190, 1750-1756.	0.2	44
25	A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy. <i>Cancer</i> , 2020, 126, 4148-4155.	2.0	41
26	Local Recurrence After Nephron-Sparing Surgery in von Hippel-Lindau Disease. <i>Urology</i> , 2007, 70, 435-439.	0.5	40
27	Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment. <i>American Journal of Surgical Pathology</i> , 2018, 42, 423-441.	2.1	38
28	Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?. <i>World Journal of Urology</i> , 2019, 37, 243-251.	1.2	37
29	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. <i>European Urology Focus</i> , 2020, 6, 1233-1239.	1.6	33
30	Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction. <i>Journal of Clinical Medicine</i> , 2020, 9, 225.	1.0	33
31	Multi-Institutional Assessment of Routine Same Day Discharge Surgery for Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 956-961.	0.2	33
32	Robot-assisted extraperitoneal laparoscopic radical prostatectomy: experience in a high-volume laparoscopy reference centre. <i>BJU International</i> , 2010, 105, 1155-1160.	1.3	32
33	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e19-e27.	0.9	31
34	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology Oncology</i> , 2020, 3, 739-747.	2.6	31
35	Current practice and access to prostate MR imaging in France. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 1125-1129.	1.8	30
36	The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance. <i>European Urology</i> , 2012, 61, 356-362.	0.9	28

#	ARTICLE	IF	CITATIONS
37	Same-day discharge surgery for robot-assisted radical prostatectomy in the era of ERAS and prehabilitation pathways: a contemporary, comparative, feasibility study. <i>World Journal of Urology</i> , 2022, 40, 1359-1365.	1.2	28
38	Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. <i>BJU International</i> , 2021, 127, 318-325.	1.3	28
39	How can we expand active surveillance criteria in patients with low and intermediate risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	1.3	27
40	Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2019, 202, 1182-1187.	0.2	25
41	Triptorelin in the management of prostate cancer. <i>Future Oncology</i> , 2013, 9, 93-102.	1.1	24
42	Challenging treatment decision-making in older urologic cancer patients. <i>World Journal of Urology</i> , 2014, 32, 299-308.	1.2	24
43	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. <i>World Journal of Urology</i> , 2014, 32, 1331-1338.	1.2	23
44	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	2.6	23
45	The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 206, 507-516.	0.2	22
46	Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high risk prostate cancer. <i>BJU International</i> , 2010, 106, 86-90.	1.3	21
47	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	0.9	21
48	Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery. <i>World Journal of Urology</i> , 2020, 38, 2493-2500.	1.2	20
49	The current role of MRI for guiding active surveillance in prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 357-365.	1.9	18
50	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 4251.	1.7	17
51	Prognostic Value of Loss of Heterozygosity at Chromosome 9p in Non-muscle-invasive Bladder Cancer. <i>Urology</i> , 2010, 76, 513.e13-513.e18.	0.5	15
52	What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. <i>World Journal of Urology</i> , 2016, 34, 617-624.	1.2	15
53	Robot-assisted laparoscopic partial nephrectomy: Early single Canadian institution experience. <i>Canadian Urological Association Journal</i> , 2013, 7, 348.	0.3	14
54	Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e1-265.e7.	0.8	14

#	ARTICLE	IF	CITATIONS
55	MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3841.	1.0	14
56	Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 160.	1.0	14
57	Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies. <i>World Journal of Urology</i> , 2019, 37, 269-275.	1.2	13
58	Extensive Biopsies and Transurethral Prostate Resection in Men With Previous Negative Biopsies and High or Increasing Prostate Specific Antigen. <i>Journal of Urology</i> , 2009, 182, 1342-1349.	0.2	12
59	MRI-guided active surveillance in prostate cancer: not yet ready for practice. <i>Nature Reviews Urology</i> , 2021, 18, 77-78.	1.9	12
60	Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies. <i>Cancers</i> , 2020, 12, 285.	1.7	12
61	A Combination of Hemostatic Agents May Safely Replace Deep Medullary Suture during Laparoscopic Partial Nephrectomy in a Pig Model. <i>Journal of Urology</i> , 2015, 193, 318-324.	0.2	11
62	Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. <i>European Urology Focus</i> , 2016, 2, 514-521.	1.6	11
63	Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic). <i>World Journal of Urology</i> , 2022, 40, 419-425.	1.2	11
64	The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. <i>BJU International</i> , 2010, 106, 1293-1297.	1.3	10
65	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. <i>World Journal of Urology</i> , 2017, 35, 1191-1197.	1.2	10
66	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. <i>World Journal of Urology</i> , 2020, 38, 663-671.	1.2	10
67	Same Day Discharge versus Inpatient Surgery for Robot-Assisted Radical Prostatectomy: A Comparative Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 661.	1.0	10
68	Impact of Hospital volume on postoperative outcomes after radical prostatectomy: A 5-Year nationwide database analysis. <i>European Urology Focus</i> , 2022, 8, 1169-1175.	1.6	10
69	Bladder Cancer in HIV-infected Adults: An Emerging Issue? Case-Reports and Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0144237.	1.1	9
70	Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. <i>Eur Urol</i> 2020;78:304-6. <i>European Urology</i> , 2020, 78, 310-313.	0.9	9
71	Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1962.	1.0	9
72	Safety and feasibility of same-day discharge laparoscopic radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , 2022, 40, 1367-1375.	1.2	9

#	ARTICLE	IF	CITATIONS
73	The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease?. <i>BJU International</i> , 2010, 105, 776-781.	1.3	8
74	Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 97-101.	2.0	8
75	Impact of the type of ultrasound probe on prostate cancer detection rate and characterization in patients undergoing MRI-targeted prostate biopsies using cognitive fusion. <i>World Journal of Urology</i> , 2014, 32, 977-983.	1.2	8
76	A prehabilitation programme implemented before robot-assisted radical prostatectomy improves perioperative outcomes and continence recovery. <i>BJU International</i> , 2022, 130, 357-363.	1.3	8
77	Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. <i>Urology</i> , 2020, 137, 126-132.	0.5	7
78	A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6354-6364.	1.3	7
79	Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey. <i>World Journal of Urology</i> , 2015, 33, 1741-1747.	1.2	6
80	Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study. <i>World Journal of Urology</i> , 2020, 38, 1735-1740.	1.2	6
81	One-day Prehabilitation Program Before Robotic Radical Prostatectomy in Daily Practice: Routine Feasibility and Benefits for Patients and Hospitals. <i>European Urology Open Science</i> , 2020, 21, 14-16.	0.2	6
82	The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies. <i>World Journal of Urology</i> , 2021, 39, 3315-3321.	1.2	6
83	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. <i>Human Pathology</i> , 2014, 45, 2006-2013.	1.1	5
84	Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 35.e15-35.e19.	0.8	5
85	Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy: The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy. <i>European Urology Oncology</i> , 2022, 5, 296-303.	2.6	5
86	A 5-Year Contemporary Nationwide Evolution of the Radical Prostatectomy Landscape. <i>European Urology Open Science</i> , 2021, 34, 1-4.	0.2	5
87	Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling. <i>Archivos Espanoles De Urologia</i> , 2015, 68, 296-306.	0.1	5
88	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. <i>Journal of Clinical Medicine</i> , 2022, 11, 1734.	1.0	5
89	Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. <i>European Urology Open Science</i> , 2022, 41, 24-34.	0.2	5
90	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. <i>Journal of Clinical Medicine</i> , 2020, 9, 3306.	1.0	4

#	ARTICLE	IF	CITATIONS
91	Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 386-392.	0.8	4
92	Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens. <i>BJU International</i> , 2022, 129, 621-626.	1.3	4
93	Same-day-discharge Robot-assisted Radical Prostatectomy: An Annual Countrywide Analysis. <i>European Urology Open Science</i> , 2022, 36, 23-25.	0.2	4
94	Confirmation by Early Oncologic Outcomes After Surgery of the Accuracy of Intermediate-risk Prostate Cancer Classification Based on Magnetic Resonance Imaging Staging and Targeted Biopsy. <i>European Urology Open Science</i> , 2020, 21, 5-8.	0.2	3
95	Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4909.	1.0	3
96	The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22. <i>American Journal of Cancer Research</i> , 2011, 1, 498-507.	1.4	3
97	Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association Française d'Urologie. <i>Cancers</i> , 2021, 13, 6070.	1.7	2
98	Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review. <i>World Journal of Urology</i> , 2022, , 1.	1.2	2
99	Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 393.	0.9	1
100	Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 734.e11-734.e17.	0.8	1
101	Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [68Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management. <i>European Urology</i> , 2022, , .	0.9	1
102	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	1.7	1
103	SEMINAL VESICLE INVASION: WHAT IS THE BEST ADJUVANT TREATMENT AFTER RADICAL PROSTATECTOMY?. <i>BJU International</i> , 2012, 109, 531-532.	1.3	0
104	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 157-162.	2.0	0
105	Editorial Comment. <i>Journal of Urology</i> , 2014, 191, 637-637.	0.2	0
106	Kallikreins Panel for Prostate Cancer Aggressiveness Prediction: More Is Not Enough. <i>European Urology Focus</i> , 2017, 3, 100-101.	1.6	0
107	Improved recovery after uro-oncology surgery: the critical role of pre- and re-habilitation. <i>World Journal of Urology</i> , 2022, 40, 1287-1287.	1.2	0
108	Magnetic Resonance Imaging-Targeted Biopsy and Pretherapeutic Prostate Cancer Risk Assessment: a Systematic Review. <i>Progres En Urologie</i> , 2022, 32, 32/6S3-32/6S18.	0.3	0